Last reviewed · How we verify
PTH analog
At a glance
| Generic name | PTH analog |
|---|---|
| Also known as | PTH(1-31) |
| Sponsor | Unigene Laboratories Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- AZP-3601 SAD and MAD Study in Healthy Subjects and Patients With Hypoparathyroidism (PHASE1, PHASE2)
- PTH Analog Type II Odontoid Fracture (PHASE2)
- The Effect of Preoperative Oral Dexamethasone Supplementation on the Outcome of Thyroidectomised Patients. (PHASE4)
- Study to Evaluate and Compare the PK Profiles of Abaloparatide-SC and Abaloparatide-sMTS in a Cohort of Healthy Men and Healthy Women. (PHASE1)
- Pediatric Chronic Kidney Disease Safety and Efficacy (PHASE3)
- Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism (PHASE2)
- Vitamin D and Coronary Calcification Study (PHASE4)
- Intravenous Paricalcitol in Chronic Hemodialysis Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PTH analog CI brief — competitive landscape report
- PTH analog updates RSS · CI watch RSS
- Unigene Laboratories Inc. portfolio CI